Daria A. Borodkina

Daria A. Borodkina

Auto-generated profile, based on publicly available information

Daria A. Borodkina

Research Institute for Complex Issues of Cardiovascular Diseases

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
DBDaria Borodkina
Daria Borodkina
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
OBOlga Barbarash
Olga Barbarash
Leptin and its receptors have been identified as key regulators of body weight and energy homeostasis. A decrease in tissue sensitivity to leptin leads to the development of obesity and metabolic disorders, such as insulin resistance and dyslipidemia. Mechanisms underlying the development of leptin resistance include mutations in the genes encoding leptin and its receptors, as well as proteins involved in self-regulation of leptin synthesis and blood–brain barrier permeability. Leptin resistance encompasses a complex pathophysiological phenomenon with a number of potential research lines. In this review, we analyze the existing data on the methods used to diagnose leptin resistance.

15 September 2018 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
DBDaria Borodkina
Daria Borodkina
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
OBOlga Barbarash
Olga Barbarash
Despite the existing preventative and therapeutic measures, cardiovascular diseases remain the main cause of temporary disability, long-term disability, and mortality. Obesity is a major risk factor for cardiovascular diseases and their complications. However, not all fat depots have the same inflammatory, paracrine, and metabolic activities. In addition, recent studies have indicated that the accumulation of visceral fat, rather than subcutaneous fat, is associated with increased cardiometabolic risk. However, there is also evidence that increasing the area of visceral fat can help protect against lipotoxicity. This review aims to discuss the contemporary literature regarding the characteristics of the visceral, epicardial, and perivascular fat depots, as well as their associations with cardiovascular disease.

16 March 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
DBDaria Borodkina
Daria Borodkina
OAOlga Akbasheva
Olga Akbasheva
OBOlga Barbarash
Olga Barbarash
Determination of the impact of visceral obesity and epicardial adipose tissue thickness on stimulating growth factor levels during hospitalization for myocardial infarction is of potential importance for predicting outcomes and assessing the development of cardiofibrotic changes associated with maladaptive myocardial remodeling. In this study, we aimed to investigate the relationships between epicardial adipose tissue thickness, adipokine profiles, and the stimulating growth factor 2/interleukin-33 signaling system during hospitalization for myocardial infarction, and with the cardiac fibrosis extent 1-year post-MI in patients with visceral obesity. Eighty-eight patients with myocardial infarction were grouped based on their visceral obesity. Serum leptin, adiponectin, stimulating growth factor 2, and interleukin-33 levels were measured on days 1 and 12 and at 1 year. The epicardial adipose tissue widths and the cardiac fibrosis areas were measured on day 12 and at 1 year. Visceral obesity was associated with epicardial adipose tissue thickness increases, adipokine imbalances, elevated leptin levels, and lower adiponectin levels during early hospitalization, and cardiac fibrosis development. Patients without visceral obesity had higher interleukin-33 and stimulating growth factor 2 levels during early hospitalization and lower cardiac fibrosis rates. Epicardial adipose tissue thickness was positively associated with cardiac fibrosis prevalence and interleukin-33 levels and negatively associated with stimulating growth factor 2 levels. The cardiac fibrosis extent was negatively associated with interleukin-33 levels and positively associated with stimulating growth factor 2 levels. Increases in epicardial adipose tissue thickness are associated with cardiac fibrosis development 1-year post-myocardial infarction and are higher in patients with visceral obesity. The metabolic activity of the epicardial adipose tissue is associated with elevated interleukin-33 and reduced stimulating growth factor 2 levels.

7 June 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
DBDaria Borodkina
Daria Borodkina
OAOlga Akbasheva
Olga Akbasheva
OBOlga Barbarash
Olga Barbarash
The aim of this study was to determine the relationship between the thickness of epicardial adipose tissue (EAT) and perivascular adipose tissue (PVAT) and the adipokine-cytokine profile of patients with coronary heart disease, which can be of significant importance for predicting the course of cardiovascular disease (CVD). Eighty-four patients with CVD were assessed and divided into two groups based on the presence of visceral obesity (VO). In patients with VO, the thickness of the epicardial deposits of the left and right ventricles were 1.75 and 1.43 times greater, respectively, than in patients without VO. For patients with VO, the prevalence of the volume of the left anterior descending artery was 10% higher, and the middle third of the envelope artery was 28% higher, when compared to patients without VO. When evaluating inflammatory status, it was established that the concentration of tumor necrosis factor-α, interleukin (IL)-1β, and leptin in the blood serum of patients with VO exceeded the values of patients without VO. The level of anti-inflammatory IL-10 was 2-times lower in patients with VO. The findings of this study show that increased EAT and PVAT are independent risk factors of CVD, as well as a possible model for the assessment of drug effectiveness for CVD.

13 April 2019 in Kardiologiia
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
DBD. A. Borodkina
D. A. Borodkina
EBE. V. Belik
E. V. Belik
OAO. E. Akbasheva
O. E. Akbasheva
EPE. I. Palicheva
E. I. Palicheva
OBOlga Barbarash
Olga Barbarash
Ghrelin is a multifunctional peptide hormone, mainly synthesized by P / D1 cells of the stomach fundus mucosa. Its basic effect, which is realized via GHS-R1 α receptor in the arcuate and the ventromedial nucleuses of hypothalamus, is stimulation of the synthesis of pituitary hormones. Ghrelin is involved in control of appetite and energy balance, regulation of carbohydrate and lipid metabolism, cell proliferation and apoptosis, as well as modulation of functioning of gastrointestinal, cardiovascular, pulmonary and immune systems. It was found that cardiomyocytes are able to synthesize ghrelin. High concentrations of GHS-R1α in the heart and major blood vessels evidence for its possible participation in functioning of cardiovascular system. Ghrelin inhibits apoptosis of cardiomyocytes and endothelial cells, and improves the functioning of the left ventricle (LV) after injury of ischemia-reperfusion mechanism. In rats with heart failure (HF) ghrelin improves LV function and attenuates development of cardiac cachexia. In addition, ghrelin exerts vasodilatory effects in humans, improves cardiac function and reduces peripheral vascular resistance in patients with chronic HF. The review contains of the predictive value of ghrelin in the development and prevention of cardiovascular disease.

15 September 2017 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
DBDaria A. Borodkina
Daria A. Borodkina
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
LKLudmila V. Kvitkova
Ludmila V. Kvitkova
OBOlga Barbarash
Olga Barbarash
БАБородкина Дарья Андреевна
Бородкина Дарья Андреевна
БЛБарбараш Ольга Леонидовна
Барбараш Ольга Леонидовна
Today, despite all the measures taken, cardiovascular diseases remain the main cause of temporary invalidization, disability and mortality. Obesity is a major risk factor of cardiovascular diseases and complications from them. However, not all fat depots have the same proinflammatory, paracrine and metabolic activity. Recent studies have shown that the accumulation of visceral fat, and not subcutaneous fat, is associated with an increase in cardiometabolic risk. At the same time, there is evidence that an increase in the area of visceral fat is a protective mechanism against lipotoxicity. The purpose of this review is to discuss current literature data reflecting the characteristics of the visceral, epicardial and perivascular fat depots, and also their association with cardiovascular diseases.